Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 13, No 4 (2015) > Article

DOI: 10.14704/nq.2015.13.4.873

Update on Sexsomnia, Sleep Related Sexual Seizures, and Forensic Implications

Carlos H. Schenck

Abstract

The first classification of sleep-related disorders and abnormal sexual behaviors and experiences was published in 2007. Parasomnias (abnormal sleep-related behaviors and experiences) and sleep-related epileptic seizures were the most frequently reported disorders, apart from Kleine-Levin syndrome (periodic hypersomnia with abnormal wakeful sexual behaviors). The first set of conditions were named sexsomnia (sleepsex) and epileptic (ictal) sexsomnia, respectively. Sexsomnia usually emerges during confusional arousals (CAs) from delta non-REM sleep (N3 sleep), either associated or unassociated with obstructive sleep apnea (OSA). We now report an additional 16 cases of sexsomnia and 2 cases of ictal sexsomnia (temporal lobe epilepsy; bupropion-induced seizures) published from 2007-2014, based on a literature search in PubMed and Embase. The demographics of the second group of 16 sexsomnia cases were similar to those of the first group of 31 cases, in regards to male gender predominance (75% vs. 81%); age at presentation (39 yrs vs. 32 yrs); age of onset (33 yrs vs. 26 yrs); and duration of sexsomnia in males (5.6 yrs vs. 8.3 yrs). The female groups were too small to compare. The distribution of sexual behaviors across the groups was generally comparable in regards to sexual vocalizations, masturbation, fondling, and intercourse/attempted intercourse. Amnesia for the sexsomnia by the affected person was 100% in both groups. Video-polysomnographic studies were conducted in nearly all patients in both groups, and provided important diagnostic findings in almost all patients. The mean number of parasomnias per patient was 1.9+1.4 vs. 2.2+1.0, respectively, with the range extending up to 5 parasomnias per patient. In both groups, a non-REM sleep parasomnia (disorder of arousal [DOA]) was the main cause of the sexsomnia (75% vs. 90%), including a comparable percentage in each group having obstructive sleep apnea (OSA) as the presumed trigger for a DOA with sexsomnia (18.7% vs. 12.9%), which was strongly supported by the control of both sexsomnia and OSA with therapy of OSA with nasal CPAP in 100% (4/4) of treated cases. Overall treatment efficacy was very high in the combined groups (82% [18/22]). Eight novel findings on sexsomnia and ictal sexsomnia were identified. The forensic implications of sexsomnia are discussed.

Keywords

sexsomnia; sleepsex; sexual behaviors of sleep; temporal lobe epilepsy; ictal orgasm; epileptic sexsomnia; polysomnography; non-REM sleep parasomnia; confusional arousals; obstructive sleep apnea; REM sleep behavior disorder; clonazepam; SSRI; bupropion;

Full Text

PDF

References

Flibanserin (also Flibanserin or BIMT-17) is a non-hormonal treatment for hypolibidemia in women. The main symptom of hypolibidemia is a total absence or reduction of sexual desire for various reasons: hormonal disorder, postpartum depression, premenopause, etc. Being an agonist of 5-HT1A and 5-HT2A, the substance directly affects "the pleasure center" - hypothalamus, increasing the levels of dopamine and noradrenaline in it. In this way, Flibanserin activates the feeling of excitement through the central nervous system.

Unfortunately, female Viagra not suitable for everyone, so be sure to check with your doctor about any contraindications before you buy Flibanserin.

In addition to Fliban on the same basis, you can also buy Addyi - a sensational drug of the American pharmaceutical company Sprout Pharmaceuticals, which, in fact, and brought Flibanserin to the world market. Unfortunately, Fliban and Addyi currently have no competitors, but there are rumors that another certified drug on a similar basis is already under development and will be available for purchase in 2018.

Which is better to buy: Addyi or Fliban?
As stated above, Addyi and Fliban have the same active ingredient, Flibanserin. This means that the properties and characteristics of these drugs are absolutely identical. The only difference is that the creators of Addyi spent a lot of money on the development of the formula, as well as on its research and subsequent promotion of the brand. What did the creators of Fliban do? They simply released the drug using a ready-made formula. Because of this, the prices of these medicines are strikingly different.